MiNK Therapeutics, Inc. (INKT)
(Real Time Quote from BATS)
$0.78 USD
+0.01 (0.65%)
Updated Sep 12, 2024 02:38 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Price, Consensus and EPS Surprise
INKT 0.78 +0.01(0.65%)
Will INKT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for INKT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INKT
MiNK Therapeutics, Inc. (INKT) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for July 11th
INKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy
MiNK Therapeutics, Inc. (INKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
MiNK Therapeutics, Inc. (INKT) Upgraded to Buy: What Does It Mean for the Stock?
Other News for INKT
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
Analysts Conflicted on These Healthcare Names: MiNK Therapeutics (INKT), Silence Therapeutics (SLN) and Mersana Therapeutics (MRSN)
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q2 2024
MiNK Therapeutics’ Promising Clinical Trials and Strategic Expansion Set to Enhance Stock Value
MiNK Reports Second Quarter 2024 Results and Business Update